Limits...
The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.

Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ - Onco Targets Ther (2015)

Bottom Line: Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed.Primary results were summarized by using a fixed-effects model or a random-effects model.OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.

ABSTRACT
In the last decade, osteopontin (OPN) was identified as one of the important proteins that promote the metastasis of tumor. However, the association between OPN overexpression and clinical outcome of non-small-cell lung cancer (NSCLC) was unclear. The purpose of this study is to investigate the role of OPN in NSCLC patients. A total of 13 studies are included to explore the relationship between the OPN elevation and the overall survival (OS) and disease-free survival (DFS) in NSCLC patients. We searched for related articles in PubMed, Web of Science, Google Scholar, and Cochrane Library databases, which were published before January 31, 2015. Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed. Primary results were summarized by using a fixed-effects model or a random-effects model. The stratified analyses in subgroups were also performed. Thirteen cohort studies, which involved 1,630 patients, were included. Subgroup analyses were performed by area and test method of OPN. We found that OPN was significantly associated with poor OS (HR =2.20, 95% CI 1.71-2.83, P<0.001) and DFS (HR =2.11, 95% CI 1.62-2.74, P<0.001) in NSCLC patients. OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001). The Egger's test suggested that there was no publication bias in OS studies (P=0.062) and DFS studies (P=0.740). These data indicate that OPN seems to have a significant predictive potential in estimating survival in NSCLC.

No MeSH data available.


Related in: MedlinePlus

Meta-analysis of the association between OPN overexpression and tumor TNM stage of NSCLC.Note: The summary OR and 95% CIs were also shown (according to the fixed-effect estimations).Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer; OR, odds ratio; CI, confidence interval.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664515&req=5

f4-ott-8-3513: Meta-analysis of the association between OPN overexpression and tumor TNM stage of NSCLC.Note: The summary OR and 95% CIs were also shown (according to the fixed-effect estimations).Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer; OR, odds ratio; CI, confidence interval.

Mentions: Three studies reported data on OPN expression and tumor TNM stage in NSCLC.17,24,25 High OPN expression seemed to be associated with high tumor stage (III and IV) in two studies and low tumor stage in one study. Combined data from all the three studies showed a trend for a correlation between high OPN expression and high tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61–4.11, P<0.001) (Figure 4) without any heterogeneity (I2=0%, P=0.417). Regrettably, only two studies provided relevant data on the correlation of OPN with tumor grade.22,24 The pooled analysis could not be performed.


The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.

Wang Y, Yang J, Liu H, Bi JR, Liu Y, Chen YY, Cao JY, Lu YJ - Onco Targets Ther (2015)

Meta-analysis of the association between OPN overexpression and tumor TNM stage of NSCLC.Note: The summary OR and 95% CIs were also shown (according to the fixed-effect estimations).Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer; OR, odds ratio; CI, confidence interval.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664515&req=5

f4-ott-8-3513: Meta-analysis of the association between OPN overexpression and tumor TNM stage of NSCLC.Note: The summary OR and 95% CIs were also shown (according to the fixed-effect estimations).Abbreviations: OPN, osteopontin; NSCLC, non-small-cell lung cancer; OR, odds ratio; CI, confidence interval.
Mentions: Three studies reported data on OPN expression and tumor TNM stage in NSCLC.17,24,25 High OPN expression seemed to be associated with high tumor stage (III and IV) in two studies and low tumor stage in one study. Combined data from all the three studies showed a trend for a correlation between high OPN expression and high tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61–4.11, P<0.001) (Figure 4) without any heterogeneity (I2=0%, P=0.417). Regrettably, only two studies provided relevant data on the correlation of OPN with tumor grade.22,24 The pooled analysis could not be performed.

Bottom Line: Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed.Primary results were summarized by using a fixed-effects model or a random-effects model.OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.

ABSTRACT
In the last decade, osteopontin (OPN) was identified as one of the important proteins that promote the metastasis of tumor. However, the association between OPN overexpression and clinical outcome of non-small-cell lung cancer (NSCLC) was unclear. The purpose of this study is to investigate the role of OPN in NSCLC patients. A total of 13 studies are included to explore the relationship between the OPN elevation and the overall survival (OS) and disease-free survival (DFS) in NSCLC patients. We searched for related articles in PubMed, Web of Science, Google Scholar, and Cochrane Library databases, which were published before January 31, 2015. Hazard ratio (HR), odds ratio (OR), and 95% confidence interval (CI) in the high OPN expression group compared with the low OPN expression group were calculated and analyzed. Primary results were summarized by using a fixed-effects model or a random-effects model. The stratified analyses in subgroups were also performed. Thirteen cohort studies, which involved 1,630 patients, were included. Subgroup analyses were performed by area and test method of OPN. We found that OPN was significantly associated with poor OS (HR =2.20, 95% CI 1.71-2.83, P<0.001) and DFS (HR =2.11, 95% CI 1.62-2.74, P<0.001) in NSCLC patients. OPN overexpression tended to be associated with the presence of advanced tumor TNM stage (III and IV) (OR =2.57, 95% CI 1.61-4.11, P<0.001). The Egger's test suggested that there was no publication bias in OS studies (P=0.062) and DFS studies (P=0.740). These data indicate that OPN seems to have a significant predictive potential in estimating survival in NSCLC.

No MeSH data available.


Related in: MedlinePlus